SCHEMBL7528673

SCHEMBL7528673

CCOP(=O)(OCC)c1cccc(-c2ccc(CO)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
PRKCI P41743 1/20 0.36
BCL2 P10415 1/20 0.36
LTA4H P09960 1/20 0.36
EPHX2 P34913 1/20 0.36
AOC3 Q16853 2/20 0.36
MGLL Q99685 1/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7526320 0.86 NPSR1 (0.41) MEN1KMT2APOLBNPSR1RXRA
SCHEMBL7195090 0.86 NPSR1 (0.41) MEN1KMT2APOLBNPSR1RXRA
SCHEMBL12229703 0.85 MEN1 (0.53) MEN1KMT2APOLBNPSR1HPGD
SCHEMBL7745491 0.80 POLB (0.47) MEN1KMT2APOLBNPSR1LTA4H
SCHEMBL7525626 0.79 CYP4F2 (0.44) MEN1KMT2APOLBNPSR1MAPT
SCHEMBL7532193 0.79 NPSR1 (0.44) MEN1KMT2APOLBNPSR1HPGD
SCHEMBL7528685 0.75 ADAMTS4 (0.37) MAPTHPGDBCL2MGLLPRMT5
SCHEMBL18780699 0.74 ABL1 (0.51) MEN1KMT2AMAPTHPGD
SCHEMBL4411677 0.73 NPSR1 (0.47) MEN1KMT2APOLBNPSR1LTA4H
SCHEMBL13636979 0.73 NPSR1 (0.47) MEN1KMT2APOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-6486141-B2 TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. MERCK FROSST CANADA & CO. (CA) 2002-11-26 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) MERCK FROSST CANADA LTD. (CA) 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) PTPRO, PPM1B, PTPA MEN1 4625/4885KMT2A 3404/4885POLB 2457/4885
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO MEN1 4448/4885KMT2A 3568/4885POLB 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.